Background The prevalence of diabetes is growing, and diabetes is an independent risk
factor for both atrial fibrillation (AF) and stroke. However, the relative effectiveness and safety …

Background: In patients with nonvalvular AF enrolled in ROCKET AF, rivaroxaban was
noninferior to warfarin for prevention of stroke and systemic embolism and caused less …

Background The prevalence of both atrial fibrillation (AF) and diabetes mellitus (DM) are
rising, and these conditions often occur together. Also, DM is an independent risk factor for …

Background Diabetes increases a patient's risk of developing atrial fibrillation by 49%.
Patients with nonvalvular atrial fibrillation are at a fivefold increased risk of stroke and die …

Objective To address gaps in the data comparing non–vitamin K antagonist oral
anticoagulants (NOACs) and warfarin among patients with nonvalvular atrial fibrillation …

Aim To compare the risk of diabetes development in patients with atrial fibrillation (AF)
treated with non‐vitamin K antagonist oral anticoagulants (NOACs) and warfarin. Materials …

Aims This meta-analysis was conducted to compare the efficacy and safety of rivaroxaban
with warfarin in patients with atrial fibrillation (AF) and diabetes mellitus. Methods PubMed …

Purpose With the aim of recommending proper anticoagulation for patients with atrial
fibrillation (AF) and diabetes mellitus, we performed the network meta-analysis comparing …

BACKGROUND Diabetes mellitus (DM) is frequent among patients with atrial fibrillation
(AF). The RE-LY trial permits a contemporary evaluation of comorbities, outcomes and the …

Aim To assess the effectiveness and safety of rivaroxaban vs warfarin in people with non‐
valvular atrial fibrillation and diabetes treated in routine practice. Methods Using US …